FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Daewoong Pharmaceutical Co., Ltd. said it has appointed a new executive who will help lead the company as co-CEO. The company has not officially announced the leadership change, but it plans to do so at its upcoming annual shareholders meeting, which will take place next month.
According to The Korea Herald, Daewoong Pharmaceutical is expected to name its vice president, Park Seong Soo, the new co-chief executive officer. This information was shared to the public by business insiders on Wednesday, Feb. 28.
Co-CEO System at Daewoong
Park will lead the pharmaceutical company along with Lee Chang Jae under the co-CEO corporate management system. Previously, Jeon Seng Ho managed Daewoong Pharmaceutical with Lee.
In his previous VP role, Park worked under the leadership of Jeon and Lee. At that time, he was crucial in securing the U.S. Food and Drug Administration's (FDA) approval for the Daewoong-manufactured botulinum toxin product called Nabota. This allowed the company to sell the treatment overseas.
Park Seong Soo also helped bolster the sales of this product outside of South Korea. Nabota's total sales last year reached KRW147 billion or about $110 million, and 80% of the sales came from foreign markets.
"Daewoong aims to accelerate the expansion of its overseas businesses with Park's appointment," the source said.
About Park Seong Soo
Korea's Hit News reported that Park Seong Soo held various roles in the company, and in 2009, he was promoted to Daewoong's global division head. In 2011, he led the company's operations in the United States. Lastly, he spearheaded the international launch of the pharma's gastroesophageal reflux disease (GERD) drug called Fexuclue, the 34th new drug in Korea.
Photo by: Daewoong Press Center
